← Oncology Approval Tracker

FDA DECISION ·

Xalkori

crizotinib · Pfizer

FDA approvalNew or expanded indicationInflammatory myofibroblastic tumor
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children age one or older with ALK-positive inflammatory myofibroblastic tumor that is unresectable, recurrent, or refractory.

LAMPGEN ANALYSIS

Why it matters

The ALK-selected indication expands targeted therapy to a rare mesenchymal tumor.

What research teams should watch

Verify histology and ALK testing and route pediatric patients to a center equipped for age-appropriate administration.

PRIMARY RECORDS

Sources